While 4D Molecular Therapeutics Inc has overperformed by 0.14%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FDMT rose by 30.52%, with highs and lows ranging from $17.41 to $2.23, whereas the simple moving average jumped by 46.41% in the last 200 days.
On January 13, 2025, BMO Capital Markets Downgraded 4D Molecular Therapeutics Inc (NASDAQ: FDMT) to Market Perform. A report published by Morgan Stanley on November 21, 2024, Initiated its previous ‘Underweight’ rating for FDMT. Barclays Initiated an Overweight rating on April 15, 2024, and assigned a price target of $459. Barclays initiated its ‘Overweight’ rating for FDMT, as published in its report on April 15, 2024. Goldman’s report from February 07, 2024 suggests a price prediction of $81 for FDMT shares, giving the stock a ‘Buy’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of 4D Molecular Therapeutics Inc (FDMT)
Further, the quarter-over-quarter increase in sales is 200.00%, showing a positive trend in the upcoming months.
In order to gain a clear picture of 4D Molecular Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -38.87% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.75, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.07M can be a very valuable indicator of volatility for FDMT stock. On a monthly basis, the volatility of the stock is set at 10.02%, whereas on a weekly basis, it is put at 10.21%, with a gain of 31.46% over the past seven days. Furthermore, long-term investors anticipate a median target price of $28.78, showing growth from the present price of $7.27, which can serve as yet another indication of whether FDMT is worth investing in or should be passed over.
How Do You Analyze 4D Molecular Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.75%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.97% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
